Trial Profile
PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary) ; Crizotinib; Midazolam
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors Pfizer
- 11 Dec 2023 Results (n=32) assessing the effect of steady-state lorlatinib on the metabolic enzymes cytochrome P450 (CYP) 2B6, CYP2C9, and uridine 5'-diphospho-glucuronosyltransferase (UGT) and the P-glycoprotein (P-gp) transporter, published in the Clinical Pharmacokinetics
- 20 Sep 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.